量子位 · QbitAI
分子之心 AI drug discovery progress: 18 successes in 19 projects
The report highlights progress by 分子之心 in challenging antibody design and claims accuracy twice that of AlphaFold 3. It also presents results from AI-driven drug discovery work: 18 of 19 projects were successful, and hits were reported for all six GPCR targets.

What to know
- 01
The report cites success in 18 of 19 projects and hits for all six GPCR targets.
- 02
分子之心 is described as achieving results in challenging antibody design, with claimed accuracy twice that of AlphaFold 3.
Why it matters
These reported results offer a reference point for tracking AI applications in antibody design and GPCR-target research.
AI-assisted brief. Read the source for full details. Editorial & sourcing policy


